Tvardi Therapeutics Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Pharmaceuticals
Headquarters
United States of America US
Employees
12
IPO date
Jan 31, 2014

Cara Therapeutics is a biopharmaceutical company that develops prescription medicines for severe itch and pain. Its work has centered on drug candidates that act on the body’s opioid receptors, especially the kappa opioid receptor, which it studies as a way to relieve symptoms without relying on traditional painkillers. In simple terms, it is a drug developer, not a drug distributor or clinic operator.

The company makes money the way many biotech firms do: by advancing drug programs through research, clinical testing, and regulatory review, then seeking value through licensing deals, partnerships, or eventual product sales if a medicine is approved. Its main customers are not patients directly at first, but drugmakers, healthcare systems, and eventually doctors and pharmacies if a product reaches the market. For investors, the key business question is whether its drug candidates can prove safe and effective enough to become approved treatments.

What makes Cara different is its focus on a narrow biology target rather than a broad portfolio of medicines. That gives it a clear role in the drug development chain: it tries to turn specialized science into therapies for conditions where current treatment options are limited or come with unwanted side effects.

Tvardi Therapeutics Inc Investor Relations

Address
3 Sugar Creek Ctr Blvd, Ste 525
Sugar Land, Texas
United States of America

Business Segments

Drug development

Cara Therapeutics develops medicines for conditions like itching and pain, then advances those candidates through lab work and clinical testing. It also works with outside partners on some programs.

Customers and revenue model

Management

Mr. Christopher A. Posner

President, CEO & Director

Biography unavailable

Mr. Ryan D. Maynard

Chief Financial Officer

Biography unavailable

Dr. Derek T. Chalmers D.Sc., Ph.D.

Co-Founder & Senior Advisor

Biography unavailable

Mr. Matthew Murphy

Manager of Investor Relations

Biography unavailable

1 / 4